The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships

IF 122.7 1区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Nature Reviews. Drug Discovery Pub Date : 2024-09-23 DOI:10.1038/d41573-024-00138-9

Josepine Fernow, Marie Olliver, William Couet, Sophie Lagrange, Meindert H. Lamers, Ole F. Olesen, Kristina Orrling, Michel Pieren, Derek J. Sloan, Juan José Vaquero, Timothy J. Miles, Anders Karlén

{"title":"The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships","authors":"Josepine Fernow, \n Marie Olliver, \n William Couet, \n Sophie Lagrange, \n Meindert H. Lamers, \n Ole F. Olesen, \n Kristina Orrling, \n Michel Pieren, \n Derek J. Sloan, \n Juan José Vaquero, \n Timothy J. Miles, \n Anders Karlén","doi":"10.1038/d41573-024-00138-9","DOIUrl":null,"url":null,"abstract":"The AMR Accelerator is an Innovative Medicines Initiative programme integrating nine projects with the shared goal of progressing the development of new antibiotics and building antimicrobial resistance research capability. Five years in, we reflect on the programme’s value, results and key challenge: ensuring the sustainability of assets, infrastructures and expertise. The AMR Accelerator is an Innovative Medicines Initiative programme integrating nine projects with the shared goal of progressing the development of new antibiotics and building antimicrobial resistance research capability. Five years in, we reflect on the programme’s value, results and key challenge: ensuring the sustainability of assets, infrastructures and expertise.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 1","pages":"1-2"},"PeriodicalIF":122.7000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews. Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/d41573-024-00138-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The AMR Accelerator is an Innovative Medicines Initiative programme integrating nine projects with the shared goal of progressing the development of new antibiotics and building antimicrobial resistance research capability. Five years in, we reflect on the programme’s value, results and key challenge: ensuring the sustainability of assets, infrastructures and expertise. The AMR Accelerator is an Innovative Medicines Initiative programme integrating nine projects with the shared goal of progressing the development of new antibiotics and building antimicrobial resistance research capability. Five years in, we reflect on the programme’s value, results and key challenge: ensuring the sustainability of assets, infrastructures and expertise.

Abstract Image

查看原文本刊更多论文

AMR 加速器：从单个组织到高效抗生素开发伙伴关系

抗微生物药物耐药性加速器是一项创新药物计划，整合了九个项目，其共同目标是推进新型抗生素的开发和抗微生物药物耐药性研究能力的建设。五年来，我们对该计划的价值、成果和主要挑战进行了反思：确保资产、基础设施和专业知识的可持续性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews. Drug Discovery 医学-生物工程与应用微生物

CiteScore

137.40

自引率

0.30%

发文量

227

期刊介绍： Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. Each issue includes: Highest-quality reviews and perspectives covering a broad scope. News stories investigating the hottest topics in drug discovery. Timely summaries of key primary research papers. Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.